Association between CYP2D6 polymorphisms and breast cancer outcomes [2]

JAMA

Volumn 303, Issue 6, 2010, Pages 516-517

  Dieudonné, Anne Sophie ^a   Van Belle, Vanya ^a   Neven, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYTOCHROME P450 2D6; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; LYMPH NODE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN POLYMORPHISM; TREATMENT OUTCOME; BREAST TUMOR; COHORT ANALYSIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NOTE; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; HUMANS; KAPLAN-MEIERS ESTIMATE; REPRODUCIBILITY OF RESULTS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 76749165728     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.93     Document Type: Letter

References (5)

1. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
2. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
3. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.